Polycythemia Vera - Pipeline Review, H1 2018

  • ID: 4464934
  • Report
  • 84 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Italfarmaco SpA
  • PharmaEssentia Corp
  • MORE
Polycythemia Vera - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.

Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 3 and 2 respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Italfarmaco SpA
  • PharmaEssentia Corp
  • MORE
Introduction

The Publisher's Report Coverage

Polycythemia Vera - Overview

Polycythemia Vera - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Polycythemia Vera - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycythemia Vera - Companies Involved in Therapeutics Development

AbbVie Inc

Bristol-Myers Squibb Co

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Italfarmaco SpA

Nerviano Medical Sciences Srl

PharmaEssentia Corp

SELLAS Life Sciences Group Inc

Polycythemia Vera - Drug Profiles

anagrelide hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idasanutlin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idelalisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropeginterferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycythemia Vera - Dormant Projects

Polycythemia Vera - Discontinued Products

Polycythemia Vera - Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting

Dec 10, 2017: PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting

Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting

Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid

Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera

Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting

Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation

Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan

May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M

May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases

Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition

Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Polycythemia Vera, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Polycythemia Vera - Pipeline by AbbVie Inc, H1 2018

Polycythemia Vera - Pipeline by Bristol-Myers Squibb Co, H1 2018

Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Polycythemia Vera - Pipeline by Gilead Sciences Inc, H1 2018

Polycythemia Vera - Pipeline by Italfarmaco SpA, H1 2018

Polycythemia Vera - Pipeline by Nerviano Medical Sciences Srl, H1 2018

Polycythemia Vera - Pipeline by PharmaEssentia Corp, H1 2018

Polycythemia Vera - Pipeline by SELLAS Life Sciences Group Inc, H1 2018

Polycythemia Vera - Dormant Projects, H1 2018

Polycythemia Vera - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Polycythemia Vera, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Italfarmaco SpA
  • Nerviano Medical Sciences Srl
  • PharmaEssentia Corp
  • SELLAS Life Sciences Group Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll